Welcome to our dedicated page for Materialise SEC filings (Ticker: MTLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Materialise NV files as a foreign private issuer, and its SEC reports document financial results, capital actions, and corporate disclosures for its additive manufacturing software, medical, and manufacturing businesses. Form 6-K reports include quarterly result releases, segment revenue for Materialise Medical, Materialise Software, and Materialise Manufacturing, expense categories such as R&D, sales and marketing, and general and administrative costs, cash balances, and exhibits incorporated by reference into a Form F-3 registration statement.
The company’s filings also cover Belgian-law annual report materials, share buyback program updates, treasury-share holdings, exchange execution details, and share-capital disclosures tied to its Nasdaq ADSs and Euronext-listed ordinary shares.
Materialise NV reports initial progress on its share buy-back program of up to EUR 30 million. Between 26 and 30 January 2026, the company repurchased 44,178 shares on Nasdaq at an average price of EUR 4.68 per share, for a total of EUR 206,562.
These purchases represent 0.1% of total shares outstanding, and Materialise now holds the same number of own shares. All trades were executed via the central order book, with no cross or block trades, under a discretionary mandate to an independent financial intermediary.
Materialise NV reports that its ordinary shares have begun trading on Euronext Brussels, in addition to its existing Nasdaq listing of American depositary shares representing ordinary shares. The additional listing and trading on Euronext Brussels commenced on November 20, 2025.
At an extraordinary shareholders’ meeting on November 14, 2025, shareholders adopted a new text of the company’s articles of association, which became effective upon the Euronext Brussels listing. The company emphasizes that this information does not constitute an offer of securities, that no public offering is or will be made, and that no offer of securities has been or will be made in the United States. A prospectus for the Euronext Brussels listing was approved by the FSMA on November 18, 2025.
Materialise NV reported that it has published a listing prospectus in connection with an additional listing of its ordinary shares on Euronext Brussels. This new listing is intended to complement the existing Nasdaq listing of its American depositary shares, which represent ordinary shares of the company. The prospectus was prepared under European Union and Belgian regulations and is provided as an exhibit to the report, giving investors in Europe a locally listed line of ordinary shares alongside the U.S.-listed ADSs.
Materialise NV plans an additional listing of its ordinary shares on Euronext Brussels alongside its Nasdaq ADSs. The company stated that no shares will be offered and no capital will be raised in connection with the Brussels listing. The Board also approved an up to EUR 30 million ADS buyback over Nasdaq, subject to publication of shareholder authorization in the Belgian State Gazette and completion of the Brussels listing.
Materialise will hold an extraordinary general shareholders’ meeting on November 14, 2025 at 17:00 CET to consider share capital movements and buyback authorization, updates to the articles (including introducing double voting rights for certain shares), remuneration policy approval, appointing the statutory auditor for sustainability assurance, and confirming board composition. Admission to trading requires an FSMA-approved prospectus and is subject to market conditions, with no guarantee the listing will occur.
Materialise NV (MTLS) reported Q3 2025 results with total revenue of 66,259 kEUR, down 3.5% year over year. Net profit was 1,848 kEUR and the operating result was 2,522 kEUR.
Performance varied by segment: Medical grew 10.3% to 33,296 kEUR, while Manufacturing fell 17.1% to 22,677 kEUR and Software declined 7.4% to 10,286 kEUR. Gross margin held essentially steady at 56.8%. Adjusted EBITDA was 8,428 kEUR versus 9,895 kEUR, and Adjusted EBIT margin was 4.4% compared to 6.4% a year ago.
Operating cash flow was 10,359 kEUR and capital expenditures were 5,288 kEUR. Cash and cash equivalents were 132,022 kEUR at September 30, 2025, against gross debt of 64,278 kEUR, resulting in a net cash position of 67,744 kEUR. Basic EPS was 0.03.
MTLS Q2-25 6-K highlights: Revenue €64.8 m, -5.8 % YoY; Medical +16.7 %, Software -12.1 %, Manufacturing -24.9 %. Gross profit €37.8 m, margin 58.3 % (+130 bps). Operating profit €2.7 m vs €3.8 m; net profit €0.2 m (EPS €0.00) vs €3.9 m, hurt by €3.1 m FX loss.
Adjusted EBIT €3.1 m (-21 %), margin 4.7 % (-90 bps). Adjusted EBITDA €8.3 m (-10 %), margin 12.8 %. Medical remains growth engine: adj EBITDA €10.7 m, margin 32.7 % (+360 bps). Manufacturing swung to a €0.8 m loss; Software flat.
Opex trimmed 0.8 % YoY; Q2 operating cash flow swung to –€0.03 m from €8.4 m. Cash & equivalents rose to €116.7 m; gross debt €53.7 m (vs €41.3 m), leaving net cash €63.0 m (+€2.0 m). Equity stable at €249.5 m.
No guidance provided. Strong Medical momentum and liquidity are offset by revenue contraction, FX headwinds and Manufacturing weakness.